Overview of Levocarnitine
Levocarnitine, with the NDC code 16571-0762, is a pharmaceutical product manufactured by Rising Pharma Holdings, Inc. It is used to treat conditions associated with carnitine deficiency, such as primary carnitine deficiency, and secondary carnitine deficiency due to other medical conditions or treatments.
Market Context
Current Market Status
Levocarnitine is a well-established drug in the market, and its demand is relatively stable due to its specific use cases. The drug is not among the highly priced or blockbuster drugs but is crucial for patients with carnitine deficiency.
Manufacturer and Distribution
Rising Pharma Holdings, Inc. is the manufacturer and labeler of Levocarnitine under the NDC code 16571-0762. The company is involved in the production of a wide range of pharmaceuticals, including generic and specialty drugs[1].
Price Dynamics
Current Pricing
As of the latest available data, there is no specific negotiated price or significant price reduction announced for Levocarnitine under the Medicare Drug Price Negotiation Program. This program, initiated by CMS, focuses on negotiating prices for high-cost drugs under Medicare Part D, but Levocarnitine is not listed among the selected drugs for negotiation[2].
Historical Pricing Trends
Historically, the prices of generic drugs like Levocarnitine have been relatively stable, with occasional adjustments due to market conditions and regulatory changes. However, without specific data on historical price trends for this NDC, it is challenging to predict exact price movements.
Future Price Projections
Given that Levocarnitine is not included in the CMS negotiation program, its prices are likely to remain stable or see minor adjustments based on market forces and production costs. Here are a few factors that could influence future pricing:
Generic Competition
The presence of generic versions of Levocarnitine can keep prices competitive. Since Rising Pharma Holdings, Inc. is a generic manufacturer, the prices are generally lower than those of branded drugs[1].
Regulatory Changes
Any changes in regulatory policies or drug pricing transparency laws could impact the pricing of Levocarnitine. For example, increased transparency and reporting requirements can sometimes lead to price adjustments[5].
Market Demand
Stable demand for the drug due to its specific therapeutic use ensures a consistent market presence. However, significant changes in demand due to new treatments or alternative therapies could affect pricing.
Market Analysis
Competitive Landscape
The market for carnitine supplements and prescription drugs is relatively niche but competitive. Several manufacturers produce Levocarnitine, and the competition is primarily based on pricing, quality, and distribution networks.
Patient Access and Savings
For patients, access to Levocarnitine is crucial, especially those with primary or secondary carnitine deficiency. While the drug is not part of the CMS negotiation program, patients may still benefit from generic pricing and any available discounts or patient assistance programs offered by the manufacturer or other healthcare providers.
Economic Impact
The economic impact of Levocarnitine on the broader pharmaceutical market is minimal compared to high-cost drugs like those targeted by the CMS negotiation program. However, for patients and healthcare systems, the availability of affordable generic options like Levocarnitine is significant in managing healthcare costs.
Key Takeaways
- Stable Demand: Levocarnitine has a stable demand due to its specific therapeutic use.
- Generic Pricing: As a generic drug, Levocarnitine is generally priced lower than branded alternatives.
- Regulatory Influence: Future pricing could be influenced by regulatory changes and market transparency laws.
- Competitive Market: The market for Levocarnitine is competitive, with several manufacturers producing the drug.
FAQs
What is the primary use of Levocarnitine?
Levocarnitine is used to treat conditions associated with carnitine deficiency, such as primary carnitine deficiency and secondary carnitine deficiency due to other medical conditions or treatments.
Who manufactures Levocarnitine under NDC 16571-0762?
Rising Pharma Holdings, Inc. is the manufacturer and labeler of Levocarnitine under the NDC code 16571-0762.
Is Levocarnitine part of the CMS Drug Price Negotiation Program?
No, Levocarnitine is not included in the CMS Drug Price Negotiation Program as of the latest available data.
What factors could influence the future pricing of Levocarnitine?
Future pricing could be influenced by generic competition, regulatory changes, and market demand.
How does the availability of Levocarnitine impact patients?
The availability of affordable generic Levocarnitine is significant for patients with carnitine deficiency, ensuring they have access to necessary treatment at a lower cost.
Sources
- Find-A-Code: Rising Pharma Holdings, Inc. - List of Drugs.
- CMS: Medicare Drug Price Negotiation Program - Fact Sheet.
- GlobalData: NSCLC Market - Global Drug Forecast & Market Analysis to 2025.
- YouTube: NDC Directory (March 2015).
- Oregon Department of Consumer and Business Services: Prescription Drug Price Transparency Results and Recommendations.
